A bill that would reauthorize the FDA's user fee agreements for medical devices, prescription and generic drugs and biosimilars passed the House on Wednesday. AdvaMed President and CEO Scott Whitaker praised the bill's "robust performance goals, process improvements, increased accountability and additional resources" and said the agreements will give patients better access to advanced medical care while allowing companies greater certainty as they plan for future innovations.
User fee reauthorization bill clears House
Sign up for AdvaMed SmartBrief
Medical technology news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.